DEEPA HASIJA: Open Payments
NPI 1801107040 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$552 in 24 payments from 7 companies in 2025. Trend: 2023 $152 · 2024 $201 · 2025 $552
Food & beverage: $552
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $169 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $163 |
| Otsuka America Pharmaceutical, Inc. | 4 | $103 |
| E.R. Squibb & Sons, L.L.C. | 2 | $46 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: VRAYLAR, CAPLYTA, REXULTI, COBENFY, SPRAVATO, AUSTEDO XR, ABILIFY ASIMTUFII, TRINTELLIX.
Industry payments across NV — which companies pay providers there.
